Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

Related Articles by Review for PubMed (Select 20351338)

1.

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, Remick SC, Steingart R, Tang WH; Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee.

J Natl Cancer Inst. 2010 May 5;102(9):596-604. doi: 10.1093/jnci/djq091. Epub 2010 Mar 29.

2.

Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, Leier CV, Liu G, Lenihan D, Lindenfeld J, Maitland ML, Remick SC, Tang WH.

Am Heart J. 2012 Feb;163(2):156-63. doi: 10.1016/j.ahj.2011.10.018. Review.

PMID:
22305831
3.

Treating hypertension in the very elderly.

Charpentier MM, Bundeff A.

Ann Pharmacother. 2011 Sep;45(9):1138-43. doi: 10.1345/aph.1P791. Epub 2011 Aug 18. Review.

PMID:
21852597
4.

Management of hypertension in angiogenesis inhibitor-treated patients.

Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP.

Ann Oncol. 2009 May;20(5):807-15. doi: 10.1093/annonc/mdn713. Epub 2009 Jan 15. Review.

5.

The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk.

Padwal RS, Hemmelgarn BR, Khan NA, Grover S, McAlister FA, McKay DW, Wilson T, Penner B, Burgess E, Bolli P, Hill MD, Mahon J, Myers MG, Abbott C, Schiffrin EL, Honos G, Mann K, Tremblay G, Milot A, Cloutier L, Chockalingam A, Rabkin SW, Dawes MD, Touyz RM, Bell C, Burns KD, Ruzicka M, Campbell NR, Lebel M, Tobe SW; Canadian Hypertension Education Program.

Can J Cardiol. 2008 Jun;24(6):455-63. Review.

6.

The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk.

Padwal RS, Hemmelgarn BR, Khan NA, Grover S, McKay DW, Wilson T, Penner B, Burgess E, McAlister FA, Bolli P, Hill MD, Mahon J, Myers MG, Abbott C, Schiffrin EL, Honos G, Mann K, Tremblay G, Milot A, Cloutier L, Chockalingam A, Rabkin SW, Dawes M, Touyz RM, Bell C, Burns KD, Ruzicka M, Campbell NR, Vallée M, Prasad R, Lebel M, Tobe SW; Canadian Hypertension Education Program.

Can J Cardiol. 2009 May;25(5):279-86. Review.

7.

Measurement and treatment of elevated blood pressure in the pediatric patient with chronic kidney disease.

Swinford RD, Portman RJ.

Adv Chronic Kidney Dis. 2004 Apr;11(2):143-61. Review.

PMID:
15216486
8.

Using fixed-dose combination therapies to achieve blood pressure goals.

Chrysant SG.

Clin Drug Investig. 2008;28(11):713-34. Review.

PMID:
18840014
9.

[The best of hypertension 2005].

Chamontin B.

Arch Mal Coeur Vaiss. 2006 Jan;99 Spec No 1(1):35-41. Review. French.

PMID:
16479962
10.

Goals of antihypertensive therapy.

McVeigh GE, Flack J, Grimm R.

Drugs. 1995 Feb;49(2):161-75. Review.

PMID:
7729325
11.

Nighttime blood pressure: a target for therapy?

Waeber B, Mourad JJ, O'Brien E.

Curr Hypertens Rep. 2010 Dec;12(6):474-9. doi: 10.1007/s11906-010-0152-0. Review.

PMID:
20862569
12.

Isolated systolic hypertension: pathophysiology, consequences and therapeutic benefits.

Kocemba J, Kawecka-Jaszcz K, Gryglewska B, Grodzicki T.

J Hum Hypertens. 1998 Sep;12(9):621-6. Review.

PMID:
9783491
13.

The future of antihypertensive treatment.

Israili ZH, Hernández-Hernández R, Valasco M.

Am J Ther. 2007 Mar-Apr;14(2):121-34. Review.

PMID:
17414579
14.

Treatment of hypertension in chronic kidney disease.

Toto RD.

Semin Nephrol. 2005 Nov;25(6):435-9. Review.

PMID:
16298269
15.

The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk.

Padwal RS, Hemmelgarn BR, McAlister FA, McKay DW, Grover S, Wilson T, Penner B, Burgess E, Bolli P, Hill M, Mahon J, Myers MG, Abbott C, Schiffrin EL, Honos G, Mann K, Tremblay G, Milot A, Cloutier L, Chockalingam A, Khan NA, Rabkin SW, Dawes M, Touyz RM, Tobe SW; Canadian Hypertension Education Program.

Can J Cardiol. 2007 May 15;23(7):529-38.

16.

Hypertension in people with Type 2 diabetes: knowledge-based diabetes-specific guidelines.

Working Party of the International Diabetes Federation (European Region).

Diabet Med. 2003 Dec;20(12):972-87. Review.

PMID:
14632698
17.

How early should blood pressure control be achieved for optimal cardiovascular outcomes?

Weir MR, Zappe D, Orloski LA, Sowers JR.

J Hum Hypertens. 2011 Apr;25(4):211-7. doi: 10.1038/jhh.2010.64. Epub 2010 Jul 1. Review.

PMID:
20596060
18.

[New treatment strategies for hypertension. Which guidelines and how to apply them].

Blacher J, Baes M, Marchal A, Younes W, Legedz L, Safar M.

Presse Med. 2005 Oct 22;34(18):1279-85. Review. French.

PMID:
16269990
19.

Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.

Kruzliak P, Novák J, Novák M.

Am J Hypertens. 2014 Jan;27(1):3-13. doi: 10.1093/ajh/hpt201. Epub 2013 Oct 29. Review.

PMID:
24168915
20.

Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.

Bair SM, Choueiri TK, Moslehi J.

Trends Cardiovasc Med. 2013 May;23(4):104-13. doi: 10.1016/j.tcm.2012.09.008. Epub 2013 Jan 2. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk